Olema Pharmaceuticals, Inc. (OLMA) has a negative trailing P/E of -8.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 28.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -11.30%, forward earnings yield 3.54%.
Criteria proven by this page:
Overall SharesGrow Score: 57/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -314.4 | 0.00 | -110.04 | 0.00 | - |
| 2019 | -456.1 | 14.59 | -185.80 | 0.00 | - |
| 2020 | -85.4 | -0.20 | 5.59 | 0.00 | - |
| 2021 | -5.2 | -0.02 | 1.30 | 0.00 | - |
| 2022 | -0.9 | -0.02 | 0.50 | 0.00 | - |
| 2023 | -6.6 | 0.36 | 2.50 | 0.00 | - |
| 2024 | -2.6 | -0.94 | 0.84 | 0.00 | - |
| 2025 | -13.4 | 0.89 | 4.55 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.16 | $0.00 | $-2.2M | - |
| 2019 | $-0.11 | $0.00 | $-4.32M | - |
| 2020 | $-0.58 | $0.00 | $-22.76M | - |
| 2021 | $-1.79 | $0.00 | $-70.89M | - |
| 2022 | $-2.62 | $0.00 | $-104.79M | - |
| 2023 | $-2.14 | $0.00 | $-96.66M | - |
| 2024 | $-2.20 | $0.00 | $-129.47M | - |
| 2025 | $-1.87 | $0.00 | $-162.45M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.25 | $-2.63 – $-1.97 | $2.25M | $1.15M – $3.6M | 8 |
| 2027 | $-2.47 | $-3.08 – $-1.78 | $25.4M | $11.96M – $45.41M | 7 |
| 2028 | $-1.93 | $-3.38 – $-0.56 | $125.88M | $120.28M – $131.49M | 4 |
| 2029 | $-0.94 | $-1.68 – $-0.34 | $303.8M | $155.48M – $486.52M | 2 |
| 2030 | $0.58 | $0.21 – $1.03 | $551.37M | $282.18M – $882.99M | 2 |
